



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Pavone-Gyongyosi et al.

Serial No.: 10/680,035

Group Art Unit: 1654

Filing Date: October 7, 2003

Examiner: (not yet assigned)

Title: OLIGOPEPTIDES AS COATING MATERIAL
FOR MEDICAL PRODUCTS

Atty Docket: ART-002.0 US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**TRANSMITTAL LETTER**

Sir:

Transmitted herewith are: [X] a Supplemental IDS, with a modified Form 1449 and cited references; [X] a return receipt postcard, to be filed in the above-identified patent application.

FEE FOR ADDITIONAL CLAIMS

[X] A fee for additional claims is not required.

[] A fee for additional claims is required. The additional fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXCESS CLAIMS	RATE	FEES DUE
TOTAL CLAIMS	=	=	0	\$50	= 0.00
INDEPENDENT	=	=	0	\$200	= 0.00
FIRST INTRODUCTION OF MULT. DEPENDENT CLAIM				\$360	= 0.00
TOTAL FEES DUE					= 00.00

PAYMENT OF ADDITIONAL FEES

[] A check in the amount of \$____ in payment of the fee for additional claims is transmitted herewith.

[] Please charge \$____ to Deposit Account No. 50-0268 in payment of the fee for additional claims.
A duplicate copy of this transmittal letter is transmitted herewith.

[] A check including the amount of \$____ in payment of the fee for the submission of an Information
Disclosure Statement is transmitted herewith.

- ☐ The Commissioner is hereby authorized to charge payment of any additional fees required under 37 CFR 1.16 or 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0268. A duplicate copy of this transmittal letter is transmitted herewith.

PETITION FOR EXTENSION OF TIME

- ☐ Extension is requested under 37 CFR 1.136(a), and the following extension fee is applicable for the Response filed herewith: ☐ \$120.00 for response within first month pursuant to 37 CFR 1.17(a)(1); ☐ \$450.00 for response within second month pursuant to 37 CFR 1.17(a)(2); ☐ \$1,020.00 for response within third month pursuant to 37 CFR 1.17(a)(3); ☐ \$1,590.00 for response within fourth month pursuant to 37 CFR 1.17(a)(4); ☐ \$2,160.00 for response within fifth month pursuant to 37 CFR 1.17(a)(5).
- ☐ A check including the amount of ☐ \$120.00 ☐ \$450.00 ☐ \$1020.00 ☐ \$1590.00 ☐ \$2160.00 in payment of the extension fee is transmitted herewith.
- ☒ The Commissioner is hereby authorized to charge payment of any additional fees required in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0268. A duplicate of this transmittal letter is submitted herewith.

Respectfully submitted,




Leon R. Yankwich, Reg. No. 30,237
David G. O'Brien, Reg. No. 46,125
Attorneys for Applicants
YANKWICH & ASSOCIATES, P.C.
201 Broadway
Cambridge, Massachusetts 02139
telephone: (617) 374-3700
telefax: (617) 374-0055

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Priority mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

December 14, 2004
Date



Nasim G. Memon

DEC 17 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Pavone-Gyongyosi et al.

Serial No.: 10/680,035

Group Art Unit: 1654

Filing Date: October 7, 2003

Examiner: (not yet assigned)

Title: OLIGOPEPTIDES AS COATING
MATERIAL FOR MEDICAL PRODUCTS

Atty Docket: ART-002.0 US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office. A listing of the cited documents is also enclosed, as well as copies of the documents in the list. This Statement is being submitted before the first Office Action on the merits. Pursuant to 37 C.F.R. § 1.97(b)(3), no fee is believed to be required with this submission.

US Patent Documents


U.S. Patent No. 6,159,488 issued December 12, 2000, Nagler et al.;

Foreign PublicationsWO 99/06367 published February 11, 1999, Lee et al.;
WO 99/42570 published August 26, 1999, Walsh;
WO 01/10383 published February 15, 2001, Golec et al.;
WO 01/21598 published March 29, 2001, Jacobs et al.;**Other Documents**Sata et al., *Journal of Biological Chemistry*, 273(5):33103-33106 (1998)

Applicants do not intend to represent that the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicants respectfully request that the documents submitted herein be considered and made of record in this application.

Respectfully submitted,



Leon R. Yankwich, Reg. No. 30,237
David G. O'Brien, Reg. No. 46,125
Attorneys for Applicant
YANKWICH & ASSOCIATES, P.C.
201 Broadway
Cambridge, Massachusetts 02139
telephone: (617) 374-3700
telefax: (617) 374-0055

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Priority mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

December 14, 2004

Date



Nasim G. Memon



Modified FORM PTO-1449	ATTY. DOCKET NO. ART-002.0 US	SERIAL NO. 10/680,035
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Pavone-Gyongyosi et al.	
(Use several sheets if necessary)	FILING DATE October 7, 2003	GROUP 1654

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	US 6,159,488	12/12/2000	Nagler et al.			
AB						

FOREIGN PUBLISHED APPLICATIONS

	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	TRANSLATION YES NO
AC	WO 99/06367	2/11/1999	Lee et al.			
AD	WO 99/42570	8/26/1999	Walsh			
AE	WO 01/10383	2/15/2001	Golec et al.			
AF	WO 01/21598	3/29/2001	Jacobs et al.			
AG						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AH	Sata et al., "Endothelial Cell Apoptosis Induced by Oxidized LDL Is Associated with the Down-regulation of the Cellular Caspase Inhibitor FLIP", <u>J. Bio. Chem.</u> , 273(50):33103-33106 (1998)
AI	
AJ	
AK	
EXAMINER	DATE CONSIDERED
/Christina Bradley/	09/02/2010

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609.
Draw line through citation if not in conformance and not considered. Include copy of this form with
next communication to Applicant.

sheet 1 of 1